The document discusses the next generation bioprocessing paradigm, focusing on high productivity membrane chromatography to revolutionize monoclonal antibody production by reducing costs, facility size, and product changeover times. It introduces Natrix® membrane technologies which enable flexible, single-use processes that optimize facility utilization and improve efficiency in biomanufacturing. The proposed approach aims to integrate upstream and downstream processes, ultimately lowering total manufacturing costs while enhancing speed and quality.